Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

PHASE2TerminatedINTERVENTIONAL
Enrollment

338

Participants

Timeline

Start Date

January 31, 2003

Primary Completion Date

December 31, 2008

Study Completion Date

April 30, 2009

Conditions
Breast Cancer
Interventions
DRUG

Epirubicin

100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)

Trial Locations (1)

1000

Jules Bordet Institute, Brussels

Sponsors
All Listed Sponsors
collaborator

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

collaborator

Centre Paul Strauss

OTHER

collaborator

Centre Hospitalier du Luxembourg

OTHER

collaborator

Clinique Louis Cathy - Baudour - Belgium

UNKNOWN

collaborator

HIS - Site Etterbeek - Ixelles - Belgium

UNKNOWN

collaborator

Clinique Saint Pierre Ottignies

OTHER

collaborator

Clinique Ste Elisabeth - Namur - Belgium

UNKNOWN

collaborator

University Hospital of Crete

OTHER

collaborator

Feculdade de Medicina da Universidade de Sao Paulo - Brasil

OTHER

lead

Jules Bordet Institute

OTHER

NCT00162812 - Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin | Biotech Hunter | Biotech Hunter